Diagnosis and monitoring of Alzheimer Disease with saliva biomarker BACE1 by Dr SJ Kellner and Prof M Ferchichi
*Correspondence to Author: 
Dr SJ Kellner and Prof M Ferchichi
Mesencell Biotech International Ltd, 
20-22 Wenlock Road, London, N1 
7GU, United Kingdom 
How to cite this article:
SJ Kellner and  M Ferchichi. Di
agnosis and monitoring of Alzhei
-
mer Disease with saliva biomarker 
BACE1. International Journal of Ag
ing Research, 2018, 1:21
eSciPub LLC, Houston, TX USA.
Website: http://escipub.com/
Dr SJ Kellner and Prof M Ferchichi, IJOAR, 2018 1:21
 
International Journal of Aging Research
(ISSN:2637-3742)
Research Article IJOAR (2018) 1:21
Diagnosis and monitoring of Alzheimer Disease with saliva 
biomarker BACE1
Alzheimer’s disease (AD) is characterized by the slow decline 
of cognition and functional abilities over time. The diagnosis for 
probable and possible AD relies principally on clinical criteria. 
The confirmation of the disease is made post-mortem by iden-
tifying extracellular senile plaques and intraneuronal fibrillary 
tangles in the brains of subjects with clinically defined dementia. 
However, the field critically lacks validated AD specific periph-
eral biomarkers to support the diagnosis in living patients or 
for early detection of patients at risk before symptoms appear. 
BACE1 (Beta site amyloid precursor protein cleaving enzyme 1) 
cleaves Amyloid Precursor Protein (APP) at two beta sites and 
represents a key target enzyme in the monitoring and possible 
treatment of AD. In our preliminary study, we evaluated the use-
fulness of salivary BACE1 to determine risk to develop AD in 
clinically normal patients. A preliminary in house laboratory grad-
ing system for BACE1 content in saliva was established with high 
levels of salivary BACE1 present in older patients and putatively 
at risk to develop AD. BACE1 seems to be a useful biomarker to 
help diagnose AD and to monitor disease progression, and re-
markably regression, when treated with stem cell secretome.
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Introduction 
Alzheimer’s disease (AD) is characterized by 
the slow decline of cognition and functional 
abilities over time. The diagnosis for probable 
and possible AD relies principally on clinical 
criteria and neuropsychological tests defined by 
the National Institute of Neurological Disorders 
and Stroke (NINDS) and the Alzheimer’s 
disease and Related Disorders Association 
(ADRDA) (1), mostly by assessment through a 
Mini-Mental State Examination MMSE. The 
confirmation of the disease is made post-
mortem by identifying extracellular senile 
plaques and intraneuronal fibrillary tangles in 
the brains of subjects with clinically defined 
dementia. However, the field critically lacks 
validated AD specific peripheral biomarkers to 
support the diagnosis in living patients or for 
early detection of patients at risk before 
symptoms appear. Some investigators studied 
structural Magnetic Resonance Imaging (2) as 
means for in vivo confirmation, whereas others 
concentrate on liquid biomarkers, such as 
plasma amyloid beta (Aβ)-40 and 42, albeit with 
mixed results (3). 
AD is the most common form of dementia and is 
pathologically characterized by amyloid plaques, 
neuroﬁbrillary tangles and loss of synapses in 
the brain. Neuroﬁbrillary tangles consist of 
hyperphosphorylated tau protein while ﬁbrils of 
the amyloid beta-peptide (Ab) aggregate into 
amyloid plaques (4). Smaller, oligomeric 
species of Ab have proven to be neurotoxic and 
cause synaptic dysfunction (5). Ab is a 
proteolytic product of the amyloid precursor 
protein (APP) which is sequentially cleaved in 
an amyloidogenic pathway by beta- and 
gamma-secretases (4). Beta-secretase cleaves 
APP close to the membrane, releasing a soluble 
APP beta-fragment (sAPPb). The remaining C-
terminal fragment (APP-CTFb) can then be 
cleaved by gamma-secretase at different sites 
yielding Ab-peptides of varying length, Ab40 
being the most common, while Ab42 is more 
toxic and prone to aggregate. If APP is cleaved 
in a non-amyloidogenic pathway by alpha-
secretase instead of beta-secretase, a non-toxic 
P3 fragment will be formed after the gamma-
secretase cleavage. 
Beta-site APP-cleaving enzyme 1 (BACE1), the 
beta-secretase in vivo, has been identiﬁed as a 
501-amino acid residue single transmembrane 
aspartyl protease (6). BACE1 cleaves APP at 
two beta sites and produces the C-terminal 
fragments (CTF) C99 and C89 (7). C99 is 
subsequently cleaved by presenilin (PS)-
dependent gamma-secretase complex to 
release Ab fragments. BACE1 therefore 
represents a key target enzyme in the 
monitoring and possible treatment of AD. 
However, over the last decade, it has become 
clear that BACE1 proteolytically cleaves a 
number of substrates in addition to APP. When 
experimenting with total knock out BACE1 mice, 
the extreme reduction or total absence of 
BACE1 led to neurological dysfunctions (8). 
Protocols using mesenchymal stem cells and/or 
their cell-free secretions (secretome) did not 
show these disadvantages, as, although many 
active ingredients are present and have shown 
to be beneficial, the concentration of these 
ingredients, the diverse mode of actions (i.e. 
anti-inflammatory molecules, content of alpha 
secretase neprilysin (NEP), antioxidants and 
ubiquitin carboxyl-terminal hydrolase L1) and 
long term but temporary cellular activation via 
microRNA prevent drastic changes. That being 
said, the content of amyloid beta degrading NEP 
and ubiquitin carboxyl-terminal hydrolase L1 
(UCH-L1) in the secretome of mesenchymal 
stem cells (MSCs), have been investigated in 
some detail in preclinical in vitro and in vivo 
studies (9). Also, on the production side of the 
secretome, both ingredients can be augmented 
through GMP compatible manufacturing 
processes. UCH-L1 accelerates BACE1 
degradation and affects APP processing and Ab 
production (10). 
In our preliminary study, we evaluated the 
usefulness of salivary BACE1 to determine risk 
to develop AD in clinically normal patients. 
Methods and Material 
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Salivary samples 
Salivary samples of 8 Patients were taken first 
thing in the morning, at lunchtime and evening 
before eating and drinking. Sample size was 
approximately 1 ml. 200 ul were mixed with 
same amount of protease inhibitor (Protease 
Inhibitor Cocktail, Sigma Aldrich, Switzerland). 
Samples with and without protease inhibition 
were either frozen immediately or left for 48 and 
72 hours at room temperature before freezing 
them as well at minus 20 degrees Celsius before 
analyzing. 
Saliva samples were not centrifuged or 
otherwise processed. 
ELISA 
Human Beta site APP cleaving enzyme 1 
sandwich ELISA kit (Sun Long Biotech, China) 
was used. 10 ul salivary samples and diluted 
salivary samples (1:1 with protease inhibitor) 
were processed according to standard 
procedure, measured at 450 OD and BACE 1 
concentration in pg/ml calculated with the help 
of the standard curve. 
Patients 
Patients were all healthy with no clinical signs of 
Alzheimer disease. Young patients were not 
showing any signs of mental deficiencies but 
some of the older Patients were self-assessed 
as having problems with concentration and 
memory. There were no family incidences of 
Alzheimer Disease. 
MMSE 
A German version of the mini-mental state 
examination was performed. 
Results 
Mini-Mental State Examination 
MMSE was normal in all patients. However, two 
patients had self-assessed problems with 
concentration and memory, which the MMSE did 
not pick up. 
Saliva samples 
Saliva samples from morning, midday and 
evenings were analyzed (Table 1). In all 
samples BACE1 could be detected. There was 
no clear diurnal variation, but clear differences 
in samples in 7 out of 8 Patients regarding the 
time of sampling. Levels of BACE 1 varied from 
267 pg/ml to 939 pg/ml. 
Saliva samples of three Patients were studies to 
see if BACE1 content at room temperature 
would change over 72 hours (Table 2). Fresh 
samples had a lower content of BACE1 then 
when measured after 48 respectively 72 hours. 
Fresh saliva samples were compared with 
samples stabilized with protease inhibitors 
(Table 3). Results showed a big difference 
between the two groups. 
 
Table 1: Diurnal variations to BACE 1 levels in saliva 
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Table 2: BACE1 values in saliva according to time spent before analysis 
Table 3: Influence of protease inhibitor on BACE1 content in saliva samples 
 
ELISA 
ELISA tests were straight forward; however the 
small sample size of 10 ul and the viscosity of 
saliva made it difficult to accurately and 
consistently dose the wells. 
Patients 
Our 8 patients were aged between 18 years of 
age and 62 years of age. The upper limit was 
meant to prevent including non-diagnosed early 
stages AD patients. There were 3 male and 5 
female Patients. 2 patients, both female, were 
suspected to have a certain degree of memory 
problems without any influence on their MMSE. 
Discussion 
Saliva samples are easily obtained, but variation 
in the amount of saliva is well known, with AD 
patients having more saliva production then 
normal controls. Theoretically, the total amount 
of saliva production and a weight factor would 
be needed for accuracy. Practically, although 
asked to be diligent, patients had quite a few 
variations in the time of sampling, making this in 
AD patients a difficult task.  Time of delay 
between sampling and processing the samples 
revealed remarkable differences. The initial idea 
was that BACE1 would decline with passing 
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hours before processing, which was not proven 
to be true. All the tested samples showed an 
increase of BACE1 values in the ELISA during 
the delay, however not linearly. This could be 
due to BACE1 not being freely suspended in 
saliva. Studies on animals have shown that 
within the brain, BACE1 is enriched in synaptic 
vesicles (11). Protease inhibition resulted 
consistently in higher levels of BACE1 being 
preserved in saliva. As with all tests, saliva 
sampling should follow a concise and practical 
protocol, allowing comparison within the same 
laboratory and patient setting. We established a 
protocol consisting of fasting saliva sampling 
before breakfast, with saliva allowed to pool in 
the anterior part of the mouth behind the front 
teeth with the mouth held open for 30 to 60 
seconds. Saliva was removed with flexible 
plastic non-sterile plastic pipettes and 
transferred to 1.5 ml plastic sample vials and 
stored on ice immediately. Vials with the saliva 
sample then should be frozen within 1 hour. No 
anti-protease was added, as early saliva 
samples could not be pipetted accurately due to 
foaming. 
 
Table 4: proposed Cut-off values for BACE1 saliva values 
 
 
All salivary samples tested revealed content of 
BACE 1 biomarker. Content of BACE1 varied 
considerably during daytime and with self-
sampling by the patients. In a separate study, 
this variability could be lessened by our 
sampling protocol and by doing the sampling by 
a nurse or technician. Contrary to blood as 
biomarker, saliva reacts quite closely to 
changes in CNS. BACE1 is certainly implicated 
in the AD process and thus our results with 
elevated BACE1 saliva levels associated with 
AD (separate, not published to date) and with 
beginning cognitive impairment in our group of 
patients confirm the value of saliva as biomarker 
as well as the connection between elevated 
BACE1 levels in saliva with cognitive 
impairment and AD. This will have to be 
confirmed with a bigger number of patients, but 
is in itself logical and plausible. Other 
researchers (3) have found that BACE1 levels 
in blood platelets are lowered (sic!) in AD 
patients, which does just not seem logical. 
Based on these test we have set a cut off value 
for BACE1 saliva content in AD patients, 
patients at risk and normal patients (Table 4). 
These values should be considered laboratory 
specific and should be validated freshly when 
used in another setting. We also believe that we 
can predict AD or at least a higher risk to 
develop AD at a very early time, giving hope to 
prevent further accumulation of amyloid 
aggregates and even clear existing amyloid 
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aggregates with stem cell therapy. 
Two of our patients had stem cell secretome 
treatments before and after saliva sampling. 
The secretome is a patented, cell free product 
generated from the active ingredients which 
stem cells secrete as cell to cell communication 
or as a result of being stressed by various 
degrees of hypoxia or by preconditioning of the 
stem cell media before the production of the 
secretome. The secretome can thus be adapted 
to different diseases, as we have shown in other 
studies, i.e. beneficial for cartilage regeneration 
or with more content of neuroregenerative 
substances. One of the patients was in the 
group of at risk patients to develop AD and one 
patient had normal saliva values of BACE1. 
They both received intramuscular secretome 4 
times at intervals of 2-4 weeks. Salivary BACE1 
levels sank dramatically in both patients. This 
confirms the treatment potential of AD with the 
secretome, although it is not clear which of the 
ingredients play a major role in this. As a total 
BACE1 knockout in rodents also lead to 
neurological dysfunction (8), a total block of 
BACE1 does not seem beneficial. However, the 
significant lowering of BACE1 over a long period 
of time would at least prevent new formation of 
amyloid beta aggregates and give to body a 
chance to clear aggregated proteins via the 
ubiquitin protease system. UCH-L1 in the 
secretome not only inhibits neuritic plaque 
formation, but also accelerates degradation of 
BACE1, regulates APP and is a major 
component of the ubiquitin protease system (12, 
13). 
It is still early days, and we are expanding our 
stem cell preventative treatments to the 
treatment of clinically manifest cognitive 
impairment and Alzheimer disease. The saliva 
biomarker BACE1 will give us a tool to monitor 
disease progression or regression, before 
clinical signs become evident. 
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